Inovio Pharmaceuticals Inc (NASDAQ:INO) shares, rose in value on Thursday, July 10, with the stock price down by -4.14% to the previous day’s close as strong demand from buyers drove the stock to $1.39.
Actively observing the price movement in the last trading, the stock closed the session at $1.45, falling within a range of $1.38 and $1.47. The value of beta (5-year monthly) was 1.309. Referring to stock’s 52-week performance, its high was $12.33, and the low was $1.30. On the whole, INO has fluctuated by -37.39% over the past month.
With the market capitalization of Inovio Pharmaceuticals Inc currently standing at about $70.83 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that INO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of INO currently trading nearly -26.11% and -28.74% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.18, while the 7-day volatility ratio is showing 9.83% which for the 30-day chart, stands at 8.13%. Furthermore, Inovio Pharmaceuticals Inc (INO)’s beta value is 1.41.
A comparison of Inovio Pharmaceuticals Inc (INO) with its peers suggests the former has fared considerably weaker in the market. INO showed an intraday change of -4.14% in last session, and over the past year, it shrunk by -24.04%%.
Data on historical trading for Inovio Pharmaceuticals Inc (NASDAQ:INO) indicates that the trading volumes over the past 10 days have averaged 5.03 and over the past 3 months, they’ve averaged 1.28 million. According to company’s latest data on outstanding shares, there are 50.96 million shares outstanding.
Nearly 0.79% of Inovio Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 26.69% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.46 million shares as on 2025-06-13, resulting in a short ratio of 9.44. According to the data, the short interest in Inovio Pharmaceuticals Inc (INO) stood at 1774.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 7.01 million. The stock has fallen by -83.99% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the INO stock heading into the next quarter.
